BridgeMD
FINISHER – Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage
EU CTIS ID: 2024-512314-17-00
What this study is testing
To analyze impact on outcome of an anti-inflammatory treatment with dexamethasone in patients with acute aneurysmal subarachnoid hemorrhage with or without an initial inflammatory signature in peripheral blood compared to placebo.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female subjects, equal or older than 18 years old
- Written consent to participate in the study by the patient or his legal representative (emergency inclusion by next of kin or consultant physician under the responsibility of the principal investigator is possible))
- Confirmed diagnosis of aneurysmal SAH and onset within 48 hours before inclusion
You likely can't join if
- SAH due to any other cause than aneurysm rupture (e.g. traumatic, arteriovenous malformation (AVM), fistula, dissection)
- Known ulceration in the gastro-intestinal tract
- History of gastro-intestinal bleeding
- Long-term treatment with corticosteroids prior SAH
- Any condition that, in the judgement of the Investigator, could impose hazards to the patient if study therapy is initiated or affects the participation of the patient in the study
- Patients with obvious evidence of irreparable brainstem or thalamic injury
See the full eligibility criteria
- Male or female subjects, equal or older than 18 years old
- Written consent to participate in the study by the patient or his legal representative (emergency inclusion by next of kin or consultant physician under the responsibility of the principal investigator is possible))
- Confirmed diagnosis of aneurysmal SAH and onset within 48 hours before inclusion
- SAH due to any other cause than aneurysm rupture (e.g. traumatic, arteriovenous malformation (AVM), fistula, dissection)
- Known ulceration in the gastro-intestinal tract
- History of gastro-intestinal bleeding
- Long-term treatment with corticosteroids prior SAH
- Any condition that, in the judgement of the Investigator, could impose hazards to the patient if study therapy is initiated or affects the participation of the patient in the study
- Patients with obvious evidence of irreparable brainstem or thalamic injury
- Patients with foreseeable difficulties to attend follow-ups adequately
- Subjects with a physical or psychiatric condition which at the investigator’s discretion may put the subject at risk, may confound the trial results, or may interfere with the subject’s participation in this clinical trial
- Current positive pregnancy test (e.g. β-HCG test in serum)
- Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical structure
- Severe infectious diseases (in discretion of the local investigator by clinical and laboratory parameters e.g. CRP, PCT, WBC, IL-6)
- Known angle-closure or open angle glaucoma
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.